NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
OpenAI Addresses Security Vulnerability in macOS App Certification Process 
Chinese Cars in Europe: Consumer Trust Is Shifting Fast 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
Chinese Brands Are Taking Over Brazil — And It's Just Getting Started 
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
SAN DIEGO, Feb. 14, 2017 -- Cytori Therapeutics, Inc. (NASDAQ:CYTX) announced today that it will present at the 2nd Annual Disruptive Growth & Healthcare Conference at 11:15 AM Eastern Time (8:15 AM Pacific Time) on Wednesday, February 15, 2017. The presentation will take place in the Track 3 - Nolita room at the Convene in New York City. Dr. Marc Hedrick, CEO and President of Cytori Therapeutics, will provide an update on current corporate activities and recent developments. For those interested in attending, please visit www.DisruptNYC.com for more information.
A live audio and video webcast of the presentation will be available under the investor relations section of Cytori’s website at www.cytori.com (http://ir.cytori.com). A replay of the presentation will be available for 90 days following the event. Please connect to Cytori’s website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary.
About Cytori Therapeutics
Cytori Therapeutics is a late stage cell therapy company developing autologous cell therapies from adipose tissue to treat a variety of medical conditions. Data from preclinical studies and clinical trials suggest that Cytori Cell Therapy™ acts principally by improving blood flow, modulating the immune system, and facilitating wound repair. As a result, Cytori Cell Therapy™ may provide benefits across multiple disease states and can be made available to the physician and patient at the point-of-care through Cytori’s proprietary technologies and products. For more information: visit www.cytori.com.
Cytori Therapeutics, Inc. Tiago Girao, +1 (858) 458.0900 [email protected]
